J0517 benralizumab (HCPCS) Reimbursement & Policy

HCPCS Level II code J0517 designates a 1 mg unit of benralizumab, a monoclonal antibody administered by injection for management of certain eosinophilic respiratory conditions. As a drug-specific HCPCS code, J0517 is used on medical claims to report the billed quantity of benralizumab supplied and is central to pharmacy-oncology and specialty drug reimbursement workflows nationwide. The code matters nationally because biologic therapies represent high-cost, high-impact services with complex coverage and utilization controls across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for benralizumab use, the service setting and billing implications for injectable biologics, and what to expect in payer coverage policies and billing practice. The publication summarizes common billing considerations, typical sites of service and service line implications, and provides benchmarks and policy-relevant issues where available. Data not available in the input will be noted explicitly where necessary.

Billing Code Overview

HCPCS Level II code J0517 represents an injection of benralizumab, 1 mg. The service type is therapeutic monoclonal antibody administration used for subcutaneous or injectable biologic therapy. The typical site of service is outpatient infusion/clinic or physician office settings where biologic injections are administered.

Data not available in the input.

Clinical Context

A typical patient is an adult with severe eosinophilic asthma or eosinophilic chronic rhinosinusitis refractory to standard inhaled corticosteroids and bronchodilators who is scheduled to receive subcutaneous benralizumab therapy. The patient presents to an outpatient infusion or injection clinic, allergy/immunology office, or pulmonology clinic for administration of J0517 (benralizumab, 1 mg). The clinical workflow includes verification of patient identity and insurance, review of indications and recent clinical status (exacerbation frequency, oral corticosteroid use, blood eosinophil count), documentation of any prior biologic therapy and allergic reactions, and assessment of injection site and vitals. The medication is prepared as the appropriate mg dose (per product dosing schedule), administered subcutaneously, and the patient is observed for immediate hypersensitivity or injection-site reaction per office protocol (commonly 30 minutes for first dose, shorter for maintenance doses if tolerated). Nursing documents lot number, expiration, dose administered, route (subcutaneous), site (e.g., right deltoid), and applicable modifier if required by the payer. Follow-up includes scheduling the next dose per dosing interval and documenting clinical response and any adverse events.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	Use when partial vial is discarded after administration and payor requires reporting of wasted drug.

Taxonomy Code	Specialty	Notes
`207RC0000X`	Allergy & Immunology	Common specialty administering biologic injections for severe asthma and allergic conditions.
`207RP1001X`	Pulmonary Disease	Pulmonologists commonly manage severe asthma and prescribe benralizumab.
`207L00000X`	Internal Medicine	Hospitalists or primary care physicians may coordinate therapy and referral for biologic management.
`363LF0000X`	Nursing — Registered Nurse	RNs administer subcutaneous injections in clinics and document administration.
`333600000X`	Pharmacist	Pharmacists prepare and verify biologic dosing and may bill under specialty pharmacy arrangements.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J45.50`	Severe persistent asthma, uncomplicated	Primary indication for benralizumab in patients with eosinophilic phenotype and frequent exacerbations.
`J45.51`	Severe persistent asthma with (acute) exacerbation	Used when benralizumab is administered in context of recent or frequent exacerbations.
`J45.901`	Unspecified asthma with (acute) exacerbation	Used when specific asthma subtype is not detailed but exacerbation prompts advanced therapy.
`J33.9`	Nasal polyp, unspecified	Benralizumab is used in eosinophilic chronic rhinosinusitis with nasal polyps in some clinical contexts.
`R06.02`	Shortness of breath	Symptom code often documented at visits where biologic therapy is considered or assessed.
`D72.1`	Eosinophilia	Laboratory finding supporting use of an anti-eosinophil biologic such as benralizumab.
`Z79.82`	Long term (current) use of systemic steroids	Documented when patients have chronic oral corticosteroid exposure and step-up to biologic therapy is considered.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly billed for the act of administering a subcutaneous injection when payer requires a CPT code in addition to the J-code for the drug.
`36415`	Collection of venous blood by venipuncture	Performed before initiation or periodically to obtain blood eosinophil counts or other labs related to biologic therapy monitoring.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Typical E/M level for routine follow-up visits associated with maintenance dosing and monitoring of response or adverse effects.
`99406`	Smoking cessation counseling, intermediate, 3-10 minutes	Behavioral counseling codes may be relevant for patients with asthma where counseling is provided during visits (ancillary and situational).
`99070`	Supplies and materials (e.g., clinical staff time, equipment) provided by the physician over and above those usually included with the service	Used when additional supplies or special handling for biologic preparation are required.

OpenPayer

Summary & Overview

HCPCS J0517: Injection, benralizumab, 1 mg